II INTERNATIONAL SYMPOSIUM: AMRAND BEYOND

NOVEMBER, 4th 2020 NOVEMBER, 17th 2020 DECEMBER, 1st 2020

LIVE WEBINAR

online at www.overgroup.eu

RATIONALE

Pulmonary antibody mediated rejection (AMR) after lung transplantation is an important cause of acute and chronic allograft dysfunction. It is critical that the lung transplant clinician, pathologist and immunologist have a strong understanding of the criteria for the diagnosis and assessment of AMR and of the approaches used to manage these patients. Understanding the clinical, pathological and immunological features of AMR will help to close the practice gap in specialist knowledge. We are delighted to offer for the second time this interactive educational opportunity to update the knowledge in this complex diagnostic scenario.

The interactive symposium is aimed at experienced lung transplant specialists (Pulmonologists/Respirologists, Surgeons, Pathologists, Immunologists) that should routinely work in a multidisciplinary team for a more sensitive and accurate diagnosis and appropriate management of this complication.

SCIENTIFIC COMMITTEE

Fiorella Calabrese (Padova), Deborah Levine (San Antonio), Federico Rea (Padova)



PROGRAMME

4 November 2020, 5 PM (C.E.T.)

1) Antibody-mediated rejection in lung transplantation: update in diagnosis

Introduction: D. Levine, F. Calabrese

Speakers: A. Zeevi, E. Cozzi, D. Levine, F. Calabrese

5.00-5.10

Introduction **D. Levine**, **F. Calabrese**

5.10-5.30

Donor-specific HLA antibodies A. Zeevi

5.30-5.50

Non-HLA antibodies **E. Cozzi**

5.50-6.10

Screening, monitoring, and risk assessment of lung AMR **D. Levine**

6.10-6.30

Pathological diagnosis of lung AMR- Grid update F. Calabrese

6.30-6.50

Discussion



PROGRAMME

17 November 2020, 5 PM (C.E.T.)

2) Antibody-mediated rejection in lung transplantation: how manage and treat patients?

Introduction: D. Levine, F. Calabrese

Speakers: A. Roux, F. Ius, C. Falk, E. Cozzi

5-5.10

Introduction D. Levine, F. Calabrese

5.10-5.30

Therapeutic approaches for pulmonary AMR: overview of clinical protocols **A. Roux** 5.30-5.50

Management with IgM F. lus

5.50-6.10

Immunomodulatory properties and mechanism of action of IVIG and IgM-C **C. Falk** 6.10-6.40

Round table about clinical and experimental research chair: E. Cozzi



PROGRAMME

1 December 2020, 5 PM (C.E.T.)

3) Antibody-mediated rejection in lung transplantation: let's work through difficult cases together

Introduction: D. Levine, F. Calabrese

Discussants: D. Levine, A. Zeevi, A. Roux, F. Calabrese

5.00-5.10

Introduction **D. Levine**, **F. Calabrese**

5.10-5.25 **L. Morlacchi**

5.25-5.40 **A. Jukna**

5.40-5.55 **V. Rossetti**

5.55-6.10 **D. Bennett**

6.10-6.30 Conclusion



SPEAKERS

DAVID BENNETT

FIORELLA CALABRESE

EMANUELE COZZI

CHRISTINE FALK

FABIO IUS

AGITA JUKNA

DEBORAH LEVINE

LETIZIA MORLACCHI

VALERIA ROSSETTI

ANTOINE ROUX

ADRIANA ZEEVI

SIENA

PADOVA

PADOVA

HANNOVER

HANNOVER

RIGA

SAN ANTONIO

MILANO

MILANO

PARIS

PITTSBURG

ORGANIZING SECRETARIAT AND PROVIDER



ph. 0372 23310 info@overgroup.eu www.overgroup.eu

ECM CREDITS

The congress designates this activity for a maximum of 7,5 ECM CREDITS for Medical Doctors specialized in: Pneumology, Infectivology, Thoracic Surgery, Anestesiology, Pathology, Immunology

UNCONDITIONAL SPONSORSHIP













